A Single-Arm, Open-Label, Phase II Study of Systemic and Tumor Directed Therapy for Recurrent Oligometastatic M1 Prostate Cancer
Latest Information Update: 10 Feb 2026
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Leuprorelin (Primary)
- Indications Adenocarcinoma; Cancer metastases; Prostate cancer
- Focus Therapeutic Use
Most Recent Events
- 05 Feb 2026 Planned End Date changed from 1 Jan 2027 to 1 Jan 2028.
- 05 Feb 2026 Planned primary completion date changed from 1 Jan 2026 to 1 Jan 2027.
- 28 Jan 2025 Planned End Date changed from 1 Jan 2026 to 1 Jan 2027.